Fatma Homa, Jameel Mohd, Siddiqui Arif Jamal, Kuddus Mohammed, Buali Nouha Saleh, Bahrini Insaf, Siddique Hifzur R
Molecular Cancer Genetics & Translational Research Laboratory, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India.
Department of Biology, College of Science, University of Ha'il, Hail, PO Box 2440, Kingdom of Saudi Arabia.
Phytomedicine. 2024 Sep;132:155777. doi: 10.1016/j.phymed.2024.155777. Epub 2024 May 31.
Extensive research on Lupeol's potential in cancer prevention highlights its ability to target various cancer-related factors. It regulates proliferative markers, modulates signaling pathways, including PI3K/AKT/mTOR, and influences inflammatory and apoptotic mechanisms. Additionally, Lupeol demonstrates selectivity in killing cancer cells while sparing normal cells, thus minimizing the risk of toxic effects on healthy tissues.
Therefore, we aimed to explore Lupeol's potential roles as a chemotherapeutic agent and as a sensitizer to chemotherapy by reviewing various animal-based studies published on its effects.
We conducted a comprehensive search across databases, including PubMed, PMC, Cochrane, EuroPMC, and ctri.gov.in to identify pertinent articles. Our focus was solely on published animal studies examining Lupeol's anti-cancer effects, with reviewers independently assessing bias risk and resolving discrepancies through consensus.
20 studies were shortlisted. The results demonstrated that Lupeol brings changes in the tumor volume by [Hedges's g: -6.62; 95 % CI: -8.68, -4.56; τ: 24.36, I: 96.50 %; p < 0.05] and tumor weight by [Hedges's g: -3.97; 95 % CI: -5.20, -2.49; τ: 2.70, I: 79.27 %; p <0.05]. The high I, negative Egger's value, and asymmetrical funnel plot show the publication bias among the studies. Further, Lupeol in combination with other chemotherapeutic agents showed better outcomes as compared to them alone [Hedges's g: -6.38; 95 % CI: -11.82, -0.94; τ: 46.91; I: 98.68 %; p <0.05]. Lupeol also targets various signaling molecules and pathways to exert an anti-cancer effect.
In conclusion, Lupeol significantly reduces tumor volume and weight. Combining Lupeol with other chemotherapy agents shows promise for enhancing anti-cancer effects. However, high variability among studies and evidence of publication bias suggest caution in interpreting results.
对羽扇豆醇在癌症预防方面潜力的广泛研究凸显了其针对多种癌症相关因素的能力。它可调节增殖标志物,调控包括PI3K/AKT/mTOR在内的信号通路,并影响炎症和凋亡机制。此外,羽扇豆醇在杀死癌细胞的同时对正常细胞具有选择性,从而将对健康组织产生毒性作用的风险降至最低。
因此,我们旨在通过回顾已发表的关于羽扇豆醇作用的各种动物研究,探讨其作为化疗药物和化疗增敏剂的潜在作用。
我们在包括PubMed、PMC、Cochrane、EuroPMC和ctri.gov.in在内的数据库中进行了全面检索,以确定相关文章。我们仅关注已发表的研究羽扇豆醇抗癌作用的动物研究,由评审人员独立评估偏倚风险,并通过共识解决分歧。
筛选出20项研究。结果表明,羽扇豆醇使肿瘤体积发生变化[赫奇斯g值:-6.62;95%置信区间:-8.68,-4.56;τ值:24.36,I值:96.50%;p<0.05],使肿瘤重量发生变化[赫奇斯g值:-3.97;95%置信区间:-5.20,-2.49;τ值:2.70,I值:79.27%;p<0.05]。高I值、负埃格值和不对称漏斗图显示了研究之间的发表偏倚。此外,与单独使用其他化疗药物相比,羽扇豆醇与其他化疗药物联合使用显示出更好的效果[赫奇斯g值:-6.38;95%置信区间:-11.82,-0.94;τ值:46.91;I值:98.68%;p<0.05]。羽扇豆醇还靶向各种信号分子和信号通路以发挥抗癌作用。
总之,羽扇豆醇可显著降低肿瘤体积和重量。将羽扇豆醇与其他化疗药物联合使用有望增强抗癌效果。然而,研究之间的高度变异性和发表偏倚的证据表明在解释结果时需谨慎。